The COPD treatment algorithm continues to evolve, with changing recommendations on the use of ICS s, LABA / ICS FDC s, and LABA / LAMA FDC s. This study reveals which therapies are prescribed first-line after diagnosis and how treatment evolves as patients move through additional lines of therapy. Both short-acting therapies and long-acting therapies are included, and many patients receive both rescue and maintenance therapies. Additionally, some patients receive a combination of a LAMA and a LABA / ICS FDC , and LABA / LAMA FDC s are beginning to gain traction in this.

Questions Answered in This Report:

    • How does current use of LABA / LAMA FDC s differ between patients with more or less severe disease, as categorized according to the GOLD guidelines? 
    • What closed and open combinations, including open triple combinations, are used most often, and how are these combinations sequenced within chronic treatment for COPD ? 
    • How long do patients typically receive their prescribed LAMA , LABA / ICS , or LABA / LAMA FDC , and for what reasons do they discontinue? 
    • Are patients more or less compliant with nebulized therapies versus those offered in handheld inhalers?  

Related Reports

Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast

The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15...

View Details

Chronic Obstructive Pulmonary Disease - Current Treatment - Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis

Long-acting beta2agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose...

View Details

Chronic Obstructive Pulmonary Disease - Access & Reimbursement - Detailed, Expanded Analysis (US) Inhaled COPD Therapies

Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) have access to more than a dozen long-acting bronchodilator inhal...

View Details

Chronic Obstructive Pulmonary Disease - Unmet Need - Detailed, Expanded Analysis: Moderate To Severe (US/EU)

The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse diseas...

View Details